From the Nuclear Medicine Unit.
Urology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Clin Nucl Med. 2022 Jul 1;47(7):e498-e499. doi: 10.1097/RLU.0000000000004151. Epub 2022 Apr 5.
Dual-tracer PET/CT with both 18F-FDG and 68Ga-DOTA-conjugated peptides is currently used in clinical routine for characterizing pNET (pancreatic masses suspicious for neuroendocrine tumor). We describe here the case of a 81-year-old man with a pancreatic lesion showing high 68Ga-DOTATOC uptake and mild 18F-FDG avidity, thus suggesting a well-differentiated pNET, which resulted at endoscopic ultrasound-guided fine-needle aspiration to be a clear cell renal cell carcinoma metastasis. In fact, the patient had right nephrectomy for clear cell renal cell carcinoma 27 years earlier. This case puts light on the role of PET/CT with 68Ga-DOTATOC in imaging RCC, a field which deserves to be further explored.
双示踪剂 PET/CT 使用 18F-FDG 和 68Ga-DOTA 缀合肽,目前用于临床常规诊断胰腺神经内分泌肿瘤(pNET,胰腺肿块疑似神经内分泌肿瘤)。我们在此描述了一例 81 岁男性患者,其胰腺病变显示高摄取 68Ga-DOTATOC 和轻度摄取 18F-FDG,提示为分化良好的 pNET,经内镜超声引导下细针抽吸活检证实为透明细胞肾细胞癌转移。事实上,患者在 27 年前因透明细胞肾细胞癌行右肾切除术。该病例阐明了 68Ga-DOTATOC PET/CT 在肾细胞癌成像中的作用,这一领域值得进一步探索。